Charles River Laboratories to Announce Q1 Earnings Amid Cautious Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy CRL?
Source: seekingalpha
Charles River Laboratories' stock rose 5.83% and reached a 20-day high amid positive market conditions.
The company is set to release its Q1 2023 earnings report on May 7, with a consensus EPS estimate of $1.94, reflecting a 17.1% year-over-year decline. Despite this, CRL has a strong track record of beating earnings estimates, although recent downward revisions in EPS and revenue forecasts indicate emerging concerns about future growth. The lack of upward revisions for EPS and revenue estimates suggests a cautious market outlook.
Investors are closely watching the upcoming earnings report, as it will provide insights into the company's performance and future prospects, especially in light of the recent revisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRL
Wall Street analysts forecast CRL stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 177.620
Low
185.00
Averages
226.70
High
265.00
Current: 177.620
Low
185.00
Averages
226.70
High
265.00
About CRL
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Charles River Labs Q1 Earnings Beat Estimates but Lowers FY2026 Forecast
- Earnings Beat: Charles River Laboratories exceeded Q1 earnings estimates, indicating strong performance in the biopharmaceutical services sector, although specific figures were not disclosed, this result boosts investor confidence.
- FY2026 Forecast Cut: The company lowered its FY2026 forecast, reflecting uncertainties in the future market environment, which may impact investor confidence in long-term growth.
- Analysts Maintain Positive Outlook: Despite the forecast cut, analysts remain optimistic about Charles River Labs, raising price targets, indicating strong market confidence in the company's future development.
- Positive Market Reaction: Investors reacted positively to the analysts' optimistic outlook, which may drive stock prices up in the short term, further solidifying the company's position in the biopharmaceutical services market.
See More
Charles River Laboratories Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Charles River Laboratories is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at $1.94, reflecting a 17.1% year-over-year decline, and revenue estimate at $977.44 million, down 0.7% year-over-year, indicating potential performance challenges.
- Historical Performance: Over the past two years, CRL has consistently beaten both EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence, although recent downward revisions in EPS and revenue forecasts suggest emerging concerns.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 8 downward adjustments, while revenue estimates also saw no upward revisions and 6 downward adjustments, reflecting a cautious market outlook on the company's future growth.
- Market Sentiment: Despite disruptions related to NAMs, RBC has assigned an
See More
Charles River Laboratories to Release Q1 2026 Financial Results
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, reflecting its ongoing performance and growth in the biopharmaceutical sector.
- Conference Call Details: A conference call will be held on the same day at 8:30 AM ET to discuss the financial results, allowing investors to engage and enhancing transparency and communication.
- Live Webcast and Replay: Investors will have the opportunity to listen to a live webcast of the conference call through the company's website, with a replay also available, ensuring broad dissemination and access to information.
- Company Overview: Charles River Laboratories provides essential products and services to pharmaceutical, biotechnology companies, and academic institutions globally, focusing on accelerating research and drug development to improve the discovery and safe manufacture of new therapies.
See More
RBC Capital Markets Initiates Outperform Rating on CRL Amid NAMs Disruption
- Coverage Initiation: RBC Capital Markets has initiated coverage on Charles River Laboratories (CRL) with an Outperform rating, highlighting that the company remains attractively valued despite disruptions from New Alternative Methods (NAMs) in preclinical research.
- Market Risk Assessment: Analyst Ryan Halsted noted that the use of NAMs is growing at approximately 38% annually, and with the FDA easing animal testing requirements, this poses a headwind for CRL, although the market may be overpricing this risk.
- Future Growth Expectations: Preclinical R&D is expected to accelerate into 2027, positioning CRL, as a leading contract research organization, to benefit significantly, with analysts projecting high-single-digit revenue growth in line with its long-term targets of 6%-8%.
- Price Target Setting: The RBC analyst set a price target of $215 per share for CRL, reflecting an optimistic outlook on the company's future performance, particularly in light of the impending patent cliff.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
Charles River Laboratories Partners with American Heart Association for Cardiovascular Health
- Collaborative Initiative: Charles River Laboratories has partnered with the American Heart Association to enhance awareness and prevention of cardiovascular diseases, supporting health initiatives across Greater Boston and nationwide, reflecting the company's commitment to public health.
- Health Data Support: According to the American Heart Association, heart disease remains the leading cause of death in the U.S., with heart disease and stroke accounting for one in four deaths, underscoring the importance of education and research to address persistent health risks.
- Community Engagement: This collaboration will support the American Heart Association's Heart of Boston campaign, promoting science-driven health improvements and further strengthening Charles River's corporate citizenship strategy focused on advancing human health.
- Timely Public Health Effort: Following a decline in cardiovascular mortality post-COVID-19, persistent risk factors such as high blood pressure, diabetes, and obesity highlight the need for education and public-private partnerships to ensure long-term cardiovascular health.
See More
Charles River Labs Q1 Earnings Beat Estimates but Lowers FY2026 Forecast
- Earnings Beat: Charles River Laboratories exceeded Q1 earnings estimates, indicating strong performance in the biopharmaceutical services sector, although specific figures were not disclosed, this result boosts investor confidence.
- FY2026 Forecast Cut: The company lowered its FY2026 forecast, reflecting uncertainties in the future market environment, which may impact investor confidence in long-term growth.
- Analysts Maintain Positive Outlook: Despite the forecast cut, analysts remain optimistic about Charles River Labs, raising price targets, indicating strong market confidence in the company's future development.
- Positive Market Reaction: Investors reacted positively to the analysts' optimistic outlook, which may drive stock prices up in the short term, further solidifying the company's position in the biopharmaceutical services market.
See More
Charles River Laboratories Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Charles River Laboratories is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at $1.94, reflecting a 17.1% year-over-year decline, and revenue estimate at $977.44 million, down 0.7% year-over-year, indicating potential performance challenges.
- Historical Performance: Over the past two years, CRL has consistently beaten both EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence, although recent downward revisions in EPS and revenue forecasts suggest emerging concerns.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 8 downward adjustments, while revenue estimates also saw no upward revisions and 6 downward adjustments, reflecting a cautious market outlook on the company's future growth.
- Market Sentiment: Despite disruptions related to NAMs, RBC has assigned an
See More
Charles River Laboratories to Release Q1 2026 Financial Results
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, reflecting its ongoing performance and growth in the biopharmaceutical sector.
- Conference Call Details: A conference call will be held on the same day at 8:30 AM ET to discuss the financial results, allowing investors to engage and enhancing transparency and communication.
- Live Webcast and Replay: Investors will have the opportunity to listen to a live webcast of the conference call through the company's website, with a replay also available, ensuring broad dissemination and access to information.
- Company Overview: Charles River Laboratories provides essential products and services to pharmaceutical, biotechnology companies, and academic institutions globally, focusing on accelerating research and drug development to improve the discovery and safe manufacture of new therapies.
See More
RBC Capital Markets Initiates Outperform Rating on CRL Amid NAMs Disruption
- Coverage Initiation: RBC Capital Markets has initiated coverage on Charles River Laboratories (CRL) with an Outperform rating, highlighting that the company remains attractively valued despite disruptions from New Alternative Methods (NAMs) in preclinical research.
- Market Risk Assessment: Analyst Ryan Halsted noted that the use of NAMs is growing at approximately 38% annually, and with the FDA easing animal testing requirements, this poses a headwind for CRL, although the market may be overpricing this risk.
- Future Growth Expectations: Preclinical R&D is expected to accelerate into 2027, positioning CRL, as a leading contract research organization, to benefit significantly, with analysts projecting high-single-digit revenue growth in line with its long-term targets of 6%-8%.
- Price Target Setting: The RBC analyst set a price target of $215 per share for CRL, reflecting an optimistic outlook on the company's future performance, particularly in light of the impending patent cliff.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
Charles River Laboratories Partners with American Heart Association for Cardiovascular Health
- Collaborative Initiative: Charles River Laboratories has partnered with the American Heart Association to enhance awareness and prevention of cardiovascular diseases, supporting health initiatives across Greater Boston and nationwide, reflecting the company's commitment to public health.
- Health Data Support: According to the American Heart Association, heart disease remains the leading cause of death in the U.S., with heart disease and stroke accounting for one in four deaths, underscoring the importance of education and research to address persistent health risks.
- Community Engagement: This collaboration will support the American Heart Association's Heart of Boston campaign, promoting science-driven health improvements and further strengthening Charles River's corporate citizenship strategy focused on advancing human health.
- Timely Public Health Effort: Following a decline in cardiovascular mortality post-COVID-19, persistent risk factors such as high blood pressure, diabetes, and obesity highlight the need for education and public-private partnerships to ensure long-term cardiovascular health.
See More
